{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:40:33Z","timestamp":1788871233676,"version":"build-2803163510"},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Ministry of Health & Welfare, Republic of Korea"}],"content-domain":{"domain":["lrjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.leukres.2015.01.011","type":"journal-article","created":{"date-parts":[[2015,1,29]],"date-time":"2015-01-29T02:35:28Z","timestamp":1422498928000},"page":"411-418","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Distinct predictive factors influence on achievement of early molecular response by frontline imatinib in chronic phase chronic myeloid leukemia"],"prefix":"10.1016","volume":"39","author":[{"given":"Sung-Eun","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Young","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Jeong","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo-Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye-Young","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hea-Lyun","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi-Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moon-Jung","family":"Chae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki-Hoon","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee-Jeong","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Jung","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2015.01.011_bib0115","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2015.01.011_bib0120","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.01.011_bib0125","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J Clinic Oncol"},{"key":"10.1016\/j.leukres.2015.01.011_bib0130","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)","volume":"26","author":"Hanfstein","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2015.01.011_bib0135","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.01.011_bib0140","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1182\/blood-2012-11-466037","article-title":"Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies","volume":"121","author":"Neelakantan","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.01.011_bib0145","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/ajh.23427","article-title":"Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib","volume":"88","author":"Lee","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2015.01.011_bib0150","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2015.01.011_bib0155","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2015.01.011_bib0160","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1182\/blood-2013-06-510396","article-title":"Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib","volume":"123","author":"Hughes","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.01.011_bib0165","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2014.153","article-title":"Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib","author":"Hanfstein","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2015.01.011_bib0170","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2014-03-566323","article-title":"Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline","author":"Branford","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.01.011_bib0175","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.01.011_bib0180","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.01.011_bib0185","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.leukres.2008.07.015","article-title":"Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels","volume":"33","author":"Forrest","year":"2009","journal-title":"Leukemia Res"},{"key":"10.1016\/j.leukres.2015.01.011_bib0190","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","article-title":"Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV","volume":"32","author":"Hehlmann","year":"2014","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.leukres.2015.01.011_bib0195","article-title":"TIDEL-II: frontline use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets","author":"Yeung","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.01.011_bib0200","series-title":"ASH Annual Meeting Abstract","first-page":"1675","article-title":"Early response (molecular and cytogenetic) and long-term outcomes in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): exploratory analysis of DASISION 3-Year Data","author":"Saglio","year":"2012"},{"key":"10.1016\/j.leukres.2015.01.011_bib0205","series-title":"ASH Annual Meeting Abstract","first-page":"167","author":"Hochhaus","year":"2012"},{"key":"10.1016\/j.leukres.2015.01.011_bib0210","series-title":"ASH Annual Meeting Abstract","first-page":"69","article-title":"Assessment of early molecular response as a predictor of long-term clinical outcomes in the phase 3 BELA study","author":"Brummendorf","year":"2012"},{"key":"10.1016\/j.leukres.2015.01.011_bib0215","series-title":"ASH Annual Meeting Abstract","first-page":"1678","article-title":"The BCR-ABL transcript levels at 3 and 6 months predict the long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib mesylate: a gimema CML WP analysis","author":"Castagnetti","year":"2012"},{"key":"10.1016\/j.leukres.2015.01.011_bib0220","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/ajh.23707","article-title":"BCR\/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase","volume":"89","author":"Kim","year":"2014","journal-title":"Am J Hematol"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212615000284?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212615000284?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T19:27:50Z","timestamp":1537903670000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212615000284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S0145212615000284"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2015.01.011","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Distinct predictive factors influence on achievement of early molecular response by frontline imatinib in chronic phase chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2015.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}